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Endocytosis of the somatostatin analogue, octreotide, by the
proximal tubule-derived opossum kidney (OK) cell line.
Background. Nephrotoxicity of cancer therapy using radi-
olabeled somatostatin analogues such as octreotide is due to
ultrafiltration and reuptake by proximal tubular cells (PTCs).
The mechanism of uptake is unknown. It could occur either by
receptor-mediated endocytosis via a somatostatin receptor or,
alternatively, the multiligand megalin/cubilin tandem receptor,
or by fluid-phase endocytosis. To define the mechanisms of inter-
nalization and to identify potential receptors, we have studied
the uptake and processing of octreotide by the PTC-derived
opossum kidney (OK) cell line.
Methods. We compared the kinetics of uptake and fate
of 111In-diethylenetriamine pentaacetic acid (DTPA)-D-Phe1-
octreotide and 125I-human serum albumin (125I-HSA). To de-
termine the contribution of receptor-mediated endocytosis, we
tested competition for uptake by octreotide and somatostatin
and by various megalin/cubilin ligands [receptor-associated pro-
tein (RAP), albumin, transferrin, insulin, polymixin B] or basic
amino acids. The subcellular localization of fluorescein isoth-
iocyanate (FITC)-D-Phe1-octreotide was studied by confocal
microscopy.
Results. Kinetics of uptake of 111In-DTPA-D-Phe1-octreotide
and 125I-HSA by OK cells were comparable, but only the so-
matostatin analogue was significantly retained intact. All me-
galin/cubilin ligands and basic amino acids strongly inhibited
125I-HSA uptake, but these could not compete for >50% of
111In-DTPA-D-Phe1-octreotide uptake. The same was found
for somatostatin and octreotide. The noncompetable uptake
of 111In-DTPA-D-Phe1-octreotide was comparable to the clear-
ance of Lucifer Yellow, a marker of fluid-phase endocytosis. By
confocal microscopy, FITC-D-Phe1-octreotide colocalized with
transferrin in endosomes, then accumulated in lysosomes.
Conclusion. Receptor-mediated endocytosis via me-
galin/cubilin and fluid-phase endocytosis contribute about
equally to the uptake of radiolabeled somatostatin analogues
by OK cells.
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Neuroendocrine tumors express high-affinity somato-
statin receptors (SSTRs) that allow for tumor imaging
and targeted radiotherapy using radiolabeled somato-
statin analogues, such as 111In- diethylenetriamine
pentaacetic acid (DTPA)-D-Phe1-octreotide [1]. Encour-
aging reports indicate that tumor growth can indeed be in-
hibited by such locally concentrated Auger- or b-emitting
radioligands [2, 3]. Moreover, coupling of radiometals via
a D amino acid spacer strongly prevents degradation and
favors retention in tumors. In the case of b-emitting radi-
oligands, this therapeutic approach is limited by nephro-
toxicity that is likely due to ultrafiltration and retention
by renal proximal tubular cells (PTCs) [4, 5]. Various em-
pirical procedures such as the infusion of basic amino
acids (e.g., lysine or arginine), maleate, or colchicine have
been attempted in animal models or in patients to pro-
tect kidneys by preventing accumulation of radiolabeled
peptides [6–10]. No information is available so far on
the mechanism whereby somatostatin analogues are re-
absorbed by kidney PTCs.
By kidney subcellular fractionation, as early as
1 hour after intravenous injection of 111In-DTPA-D-Phe1-
octreotide to mice, the vast majority of radioactivity
codistributed in Percoll gradients with b-galactosidase
(b-gal) activity, in a peak well-resolved from the plasma
membrane marker, alkaline phosphodiesterase I [11].
This distribution lasted for at least 1 day. Taken together,
these results strongly indicate endocytic uptake, followed
by transfer and retention in lysosomes. Undigested or in-
digestible peptides are reported to accumulate in lyso-
somes and may thereby cause additional kidney toxicity
[12, 13]. Ultrafiltered low-molecular-weight tracers can
be taken up into kidney PTCs by two major mechanisms,
either the low efficient fluid-phase endocytosis (as best
illustrated for dextran ∼ 0.1% ∗ min−1of injected dose)
[14] or the highly efficient receptor-mediated endocyto-
sis by the megalin/cubilin tandem receptor (as illustrated
for b 2-microglobulin ∼ 3% ∗ min−1) [15]. The avidity for
low-molecular-weight proteins is due to the high abun-
dance of these scavenger-like receptors, megalin and
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cubilin, at the brush border where they project an unusu-
ally large extracellular domain into the proximal tubule
lumen [15–18]. Moreover, megalin and presumably cu-
bilin recycle extremely fast between the brush border
and endosomes, allowing for ∼20 cycles of endocytic up-
take/hour [15]. These combined properties lead to opti-
mal reabsorbtion of an extremely wide variety of com-
pounds, including endogenous proteins such as albumin
and drugs such as gentamicin and polymixin B. Megalin
and/or cubilin are thus good candidates to mediate en-
docytosis of ultrafiltered octreotide by PTCs. Alterna-
tively, uptake through a specific somatostatin receptor
has to be considered. Although some reports indicate
variable expression of somatostatin receptor subtypes
1-5 in the kidney of several species, expression by PTCs
appeared limited [19, 20]. In the case of 111In-DTPA-
D-Phe1-octreotide, SSTR2 must be looked for since this
receptor subtype has the highest affinity for this somato-
statin analogue.
The aim of this study was to investigate in vitro the up-
take of a somatostatin analogue, octreotide, by the well-
differentiated opossum kidney (OK) cell line, an estab-
lished model to study renal tubular transport by PTCs.
METHODS
Reagents
Dulbecco’s modified Eagle’s medium (DMEM-F12),
fetal bovine serum (FBS), penicillin, streptomycin,
and trypsin-ethylenediaminetetraacetic acid (EDTA)
were obtained from Life Technologies (Merelbeke,
Belgium). Falcon flasks, 6-well plates Lab-TekTM
chambers (borosilicate coverglass) were from Nunc
(Merck Eurolab, Leuven, Belgium). 3-(N-morpholino)-
propanesulphonic acid (MOPS), N-(2-hydroxyethyl)-
piperazine-N′-(2-ethanesulphonic acid) (Hepes), bovine
insulin, bovine serum albumin (BSA), bovine holotrans-
ferrin, polymixin B, somatostatin (SMS 14), chloro-
quine, and Lucifer Yellow were obtained from Sigma
Aldrich (Bornem, Belgium). LysoTracker red was from
Molecular Probes (Leiden, The Netherlands). Protein-
steril Hepa 8%, used as the amino acid solution, was
obtained from Fresenius Kabi (Schelle, Belgium). Hu-
man serum albumin (HSA) (Croix-Rouge, Brussels, Bel-
gium) was radioiodinated with 125I by means of the
chloramine T method (specific activity 172 GBq/mol).
111In-DTPA-D-Phe1-octreotide (specific activity 27.7 ×
106 GBq/mol) was obtained from Tyco Healthcare (Pet-
ten, The Netherlands). Octreotide (Sandostatin) was
from Novartis Pharma (Brussels, Belgium). Recombi-
nant rat receptor-associated protein (RAP) was obtained
from RDI (Flanders, NJ, USA). Iron-saturated transfer-
rin (Sigma Chemical Co., St. Louis, MO, USA) was con-
jugated to Alexa Fluor 568 (Molecular Probes, Eugene,
OR, USA), as recommended by the manufacturer [21].
Cell culture
OK cells were grown in 75 cm2 Falcon flasks in DMEM-
F12 containing 10% (vol/vol) FBS, 100 U/mL penicillin,
and 100 lg/mL streptomycin in a 5% CO2 atmosphere at
37◦C. Confluent cell monolayers were subcultured (1:5)
twice a week after detachment by 0.5 g/L trypsin and
0.2 g/L EDTA, for 5 to 10 minutes at 37◦C. All experi-
ments were performed at passages 99-116.
Biochemical studies
OK cells were grown to confluency in 6-well plates.
After three washes with Ringer’s solution (130 mmol/L
NaCl, 4 mmol/L KCl, 1 mmol/L MgCl2, 1 mmol/L CaCl2,
5 mmol/L glucose, and 10 mmol/L Hepes) adjusted to
pH 7.4 using Tris-(hydroxymethyl)-aminomethane, cells
were incubated for the indicated time intervals with ei-
ther 3 lmol/L 125I-HSA or 1 nmol/L 111In-DTPA-D-Phe1-
octreotide in Ringer’s solution at 37◦C for endocytosis
(or 4◦C for control). No toxic effect due to the Tris-
(hydroxymethyl)-aminomethane in the buffer solution
was observed. Endocytic uptake was stopped by trans-
ferring monolayers to 4◦C. Cells were extensively washed
(10×) with ice-cold Ringer’s solution and lysed by 0.1%
(vol/vol) Triton X-100 in 10 mmol/L MOPS, pH 7.4.
Radioactivity was normalized to the cell protein con-
tent, measured by the BCA procedure (Pierce, Polylab,
Antwerp, Belgium) with reference to BSA as standard.
For pulse-chase experiments, cells were similarly in-
cubated at 37◦C for 1 hour with 3 lmol/L 125I-HSA or
1 nmol/L 111In-DTPA-D-Phe1-octreotide, washed with
ice-cold Ringer’s solution, then chased in Ringer’s solu-
tion at 37◦C. The integrity of residual 125I-HSA in medium
after 2 hours of chase was analyzed by size exclusion
gel filtration chromatography using a Sephadex G25 col-
umn (Amersham Biosciences, Uppsala, Sweden), in 0.9%
NaCl. The integrity of 111In-DTPA-D-Phe1-octreotide be-
fore and after cellular internalization was controlled by
reverse-phase chromatography (Sep-Pack C18) (Waters
Corporation, Milford, MA, USA). The columns were
equilibrated with 2 mL methanol and 5 mL distilled wa-
ter; hydrosoluble indium and radiolabeled peptide were
then eluted by 5 mL distilled water followed by 5 mL
methanol, respectively. Assays were performed on tracer
alone and on cell lysates after 1 hour tracer uptake, with-
out or following overnight preincubation with 100 lmol/L
chloroquine.
To test for competition of tracer uptake, cells were
incubated at 37◦C for 1 hour with 1 lmol/L 125I-HSA
or 1 nmol/L 111In-DTPA-D-Phe1-octreotide in the ab-
sence or presence of 1 lmol/L RAP, 100 lmol/L HSA,
100 lmol/L transferrin, 100 lmol/L insulin, 100 lmol/L
polymixin B, 100 lmol/L octreotide, and 100 lmol/L so-
matostatin (SMS 14), or a mixture of amino acids (total
concentration 20 g/L, containing 10 mmol/L L-arginine)
as used in vivo in humans [10]. In this setting, the peak
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concentration of arginine in urine was ∼ 10 mmol/L; this
concentration was accordingly selected for the in vitro
studies on OK cells.
To validate a fluorescent tracer for further mor-
phologic studies, 0.1 nmol fluorescein isothiocyanate
(FITC)-D-Phe1-octreotide, a kind gift of Novartis Pharma
(Basel, Switzerland), was labeled with Na125I (37 MBq)
using iodogen-precoated tubes ([1,3,4,6-tetrachloro-
3a-6a-diphenylglycoluril]-precoated iodination tubes)
(Iodo-Gen) (Pierce Polylab, Antwerp, Belgium) [21].
Radiolabeled peptide extraction was performed using
a Sep-Pack C18 column as described by Bakker et al
[22]. Radiolabeled peptide was eluted with ethanol. After
ethanol evaporation, 125I-FITC-D-Phe1-octreotide was
dissolved in dimethyl sulfoxide (DMSO) to a final 0.1%
concentration for cell binding assay. This concentration
of DMSO did not induce any cell toxicity. Binding ex-
periments were performed in the same conditions as for
111In-DTPA-D-Phe1-octreotide.
To determine the rate of fluid-phase endocytosis, OK
cells were incubated with 1 mg/mL Lucifer Yellow at
37◦C for 1 hour. Cells were washed (10×) with ice-cold
Ringer’s solution and lysed as described above. Fluores-
cence in 200 lL samples of cell lysates was measured
(FluoroCount) (Packard Canberra, Zellik, Belgium) (ex-
citation 425 nm; emission 530 nm), with reference to
known concentrations of Lucifer Yellow. Results were
normalized to the cell protein content.
Confocal microscopy
OK cells (∼9000/cm2) were seeded in Lab-TekTM II
chambers the day before the experiment. After three
washes with 1 mL Ringer’s solution, cells were incubated
with 10 lg/mL FITC-D-Phe1-octreotide in Ringer’s so-
lution for the indicated times. After three rinses with
Ringer’s solution, living cells were immediately ana-
lyzed using an Axiovert confocal microscope (Zeiss,
Oberkochen, Germany) coupled to an MRC 1024 confo-
cal scanning equipment (Bio-Rad, Richmond, CA, USA)
as described [23].
To test for a transit via endosomes, cells were incubated
with 10 lg/mL FITC-D-Phe1-octreotide together with
100 lg/mL Alexa Fluor 568 transferrin at 37◦C for ∼10
minutes. The megalin/cubilin dependence of this route
was evaluated by adding 1 mg/mL BSA for 5 minutes be-
fore and together with the two fluorescent tracers. To test
for lysosomal association, OK cells were preincubated for
1 hour with 75 nmol/L LysoTracker red, a lysosomal vi-
tal stain, after which 10 lg/mL FITC-D-Phe1-octreotide
was added for 60 minutes in the continued presence of
LysoTracker red, including in washing solutions.
SSTR2 expression
To search for SSTR2 expression in OK cells, and mouse
medullary thick ascending limb cells as control, cells
were homogenized in Trizol (Invitrogen, Merelbeke, Bel-
gium). RNA was extracted and reverse transcription-
polymerase chain reaction (RT-PCR) was performed as
previously described [24]. Primers for amplification of
SSTR2 were sense 5′-ATCATCAAGGTGAAGTCCT-
3′; anti-sense CAGATACTGGTTTGGAGGTCTCC.
Primers were designed for a region of the SSTR2 exon 2
that is perfectly homologous for human, mouse, and rat.
The length of amplicons was 416 bases.
Statistical analysis
Values are presented as means±SEM. The two-sample
unpaired Student t test was used to compare the uptake of
125I-HSA and 111In-DTPA-D-Phe1-octreotide alone or in
the presence of inhibitors. The statistical significance of
the difference was determined on the basis of a two-tailed
5% a error.
RESULTS
Radioligand uptake kinetics
As shown in Figure 1A, uptake of 3 lmol/L 125I-
HSA by OK cells was negligible at 4◦C but reached
35.8 ± 3.5 pmol/mg cell protein (medium clearance 11.9 ±
1.2 lL/mg cell protein; ∼1% of total activity introduced in
the assay) after 2 hours at 37◦C. At this interval, a steady
state was reached between uptake and efflux or degra-
dation. After 2 hours of chase (Fig. 2A), cell-associated
radioactivity was almost entirely released in the medium,
where it appeared on size-exclusion gel filtration chro-
matography as low-molecular-weight products, indicat-
ing full degradation of internalized 125I-HSA and release
of degradation products (Fig. 2C), although 125I-HSA was
stable in medium alone.
Uptake of 1 nmol/L 111In-DTPA-D-Phe1-octreotide
was also temperature-dependent and showed a simi-
lar kinetics but was > fivefold less effective (Fig. 1B),
the plateau after 2 hours corresponding to 2.37 ±
0.02 fmol/mg cell protein (medium clearance 1.97 ±
0.02 lL/mg cell protein; <0.2% of total radioactivity in-
troduced in the assay). To validate the use of FITC-
D-Phe1-octreotide for subsequent morphologic studies,
we radiolabeled this compound on its fluorescein moi-
ety. Uptake kinetics of 125I-FITC-D-Phe1-octreotide was
comparable to that of the 111In-labeled peptide (Fig. 1B).
In contrast to 125I-HSA, the fraction of 111In-DTPA-
D-Phe1-octreotide released after 2 hours chase did not
exceed ∼30% suggesting that the majority of internal-
ized 111In label was efficiently retained by the cells
(Fig. 2B). Further analysis by reverse-phase chromatog-
raphy demonstrated that most of the cell-associated ra-
dioactivity remained peptide-bound (Fig. 2D).
These findings are consistent with either intracellular
retention in a prelysosomal compartment or strong re-
sistance to degradation in lysosomes. That the marginal
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Fig. 1. Uptake kinetics of 125I-human serum albumin (HSA) (A),
111In-(diethylenetriamine pentaacetic acid (DTPA-D-Phe1-octreotide
and 125I-fluorescein isothiocyanate (FITC)-D-Phe1-octreotide (B) in
opossum kidney (OK) cells. (A) Cells were incubated with 3 lmol/L
125I-HSA (N = 3 to 6) at 37◦C () or at 4◦C to prevent endocytosis (N
= 3) (). (B) Incubation with 1 nmol/L 111In-DTPA-D-Phe1-octreotide
(N = 6) at 37◦C () and 4◦C () or 125I-FITC-D-Phe1-octreotide (N =
6) (). Results are means ± SEM. Curves were adjusted by nonlinear
fitting based on a hyperbolic function [U = at/(b + t)] where U is the
uptake at a given time; t is the steady state accumulation; and b is the
half time of saturation of uptake.
degradation takes place in lysosomes is supported by
the ∼ twofold inhibition when cells had been incubated
overnight with 100 lmol/L chloroquine (Fig. 2D). This
weak base both prevents access to lysosomes [25] and
suppresses the acidification of lysosomal lumen, thereby
inhibiting acid hydrolases [26].
Mechanism of endocytosis
To assess the possible role of receptor-mediated endo-
cytosis in the uptake of 111In-DTPA-D-Phe1-octreotide,
we used a panel of potential competitors, and compared
their effect on 125I-HSA uptake (Fig. 3). As expected, the
uptake of 1 lmol/L 125I-HSA was almost abrogated by
RAP, or by a 100-fold molar excess of albumin, trans-
ferrin, or insulin, indicating that all three proteins bind
to the same membrane receptor, presumably the me-
galin/cubilin complex which is known to be expressed
on OK cells [18]. Polymixin B, another megalin ligand
[27], was equally effective. The uptake of 125I-HSA was
also largely inhibited by basic amino acids, but octreotide
was poorly effective (∼30% inhibition). In contrast, all
these competitors, including 1 lmol/L RAP, were able
to significantly decrease the uptake of 111In-DTPA-D-
Phe1-octreotide, but none achieved more than a ∼50%
inhibition. For instance, when results were expressed
as 111In-DTPA-D-Phe1-octreotide clearance from the
medium, values after 1 hour of uptake fell from 1.5 ± 0.1
lL/mg cell protein without competitor to 0.7 ± 0.1 lL/mg
cell protein when albumin was added (P < 0.0001). This
pointed to the association of megalin/cubilin-mediated
endocytosis and of another mechanism.
One possibility could be concomitant receptor-
mediated endocytosis via megalin/cubilin and via somato-
statin receptors. However, even a 100,000-fold molar
excess of octreotide or somatostatin did not inhibit 111In-
DTPA-D-Phe1-octreotide uptake by more than 25% and
the simultaneous addition of albumin or transferrin did
not bring residual values down to the low level of com-
petition observed for 125I-HSA. In addition, we failed to
detect SSTR2 expression in OK cells by RT-PCR, based
on primers designed against a fully conserved sequence in
human, mouse, and rat (data not shown). Alternatively,
the ∼50% non-competable level of 111In-DTPA-D-Phe1-
octreotide uptake despite a large variety of totally unre-
lated procedures could represent fluid-phase uptake. This
interpretation is strongly supported by the similar values
of residual 111In-DTPA-D-Phe1-octreotide uptake in the
presence of the various megalin/cubilin inhibitors (0.7 ±
0.1 lL/mg cell protein after 1 hour) and the level of fluid-
phase endocytosis measured by Lucifer Yellow uptake
(0.5 ± 0.1 lL/mg cell protein after 1 hour, in excellent
agreement with a previous report [28]).
Localization by confocal laser scanning microscopy
To visualize the endocytic pathway of octreotide in OK
cells, we used a fluorescent conjugate that showed uptake
kinetics comparable with 111In-DTPA-D-Phe1-octreotide
(Fig. 1B). After 10 to 60 minutes of incubation at 37◦C,
the fluorescence showed a cytoplasmic punctate pattern.
At the early time points, FITC-D-Phe1-octreotide showed
partial co-localization with the endosomal tracer, Alexa
Fluor 568 transferrin (Fig. 4A to C); both signals de-
creased in the presence of albumin (Fig. 4D to F). Further-
more, after 60 minutes, FITC-D-Phe1-octreotide showed
a predominant colocalization with LysoTracker red, a
fluorescent probe that accumulates into lysosomes by aci-
dotropism (Fig. 5).
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Fig. 2. (A and B) Efflux after 1 hour of
uptake upon chase in tracer-free medium
(N = 6). Results are mean ± SEM. Curves
were adjusted by a bi-exponential function (R
= ae−bt + ce−dt) for 125I-human serum albu-
min (HSA) efflux and Siegel decay (R = 100 ×
[1 − (1 − e−at)b)] for 111In-diethylenetriamine
pentaacetic acid (DTPA)-D-Phe1-octreotide
efflux, where R is the residual fraction and
t is the time. (C) Size exclusion gel chro-
matography of a 2-hour chase medium after
1 hour uptake of 125I-HSA. The elution pro-
file shows that the majority of the radioac-
tivity corresponds to low-molecular-weight
metabolites (i.e., free iodine). (D) Reverse-
phase chromatography performed on 111In-
DTPA-D-Phe1-octreotide stock tracer solu-
tion and cell lysate after 1 hour incubation
with 111In-DTPA-D-Phe1-octreotide of opos-
sum kidney (OK) cells either untreated (−
chloroquine) (N = 4) or preincubated with
chloroquine (N = 2). The bars represent the
percentage of recovered hydrosoluble 111In
(i.e., not peptide-bound).
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Fig. 3. Inhibition of uptake of 1 lmol/L
125I-human serum albumin (HSA) and
1 nmol/L 111In- diethylenetriamine pen-
taacetic acid (DTPA)-D-Phe1-octreotide by
1 lmol/L receptor-associated protein (RAP),
100 lmol/L albumin, 100 lmol/L transferrin,
100 lmol/L insulin, 100 lmol/L polymixin B,
amino acids (containing 10 mmol/L arginine),
100 lmol/L octreotide, 100 lmol/L somato-
statin, or the indicated combinations. The
numbers of experiments are indicated in ital-
ics. ND is not determined. All comparisons
versus controls are statistically significant
(P < 0.05), except for the competition of in-
sulin on 111In-DTPA-D-Phe1-octreotide up-
take.
DISCUSSION
In the adult human kidney, several grams of low-
molecular-weight proteins are filtered daily. The lack of
protein in urine under physiologic conditions empha-
sizes the global efficiency of the reabsorption process
by proximal tubules [29]. The apical plasma membrane
of the PTC is equipped with an elaborate brush bor-
der surface where the multiligand megalin/cubilin tan-
dem receptors are abundantly expressed and undergo
a rapid endocytic cycle: these features maximize endo-
cytic recapture of filtered low-molecular-weight proteins.
When injected to patients, radiolabeled somatostatin
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Fig. 4. Localization by confocal microscopy of fluorescein isothiocyanate (FITC)-D-Phe1-octreotide and Alexa Fluor 568 transferrin in opossum
kidney (OK) cells after 10 minutes. (A) Red fluorescence indicates the presence of Alexa Fluor 568 transferrin in an endosomal compartment.
(B) Green fluorescence represents FITC-D-Phe1-octreotide. (C) Merge; partial colocalization of the tracers (yellow fluorescence). (D to F) The
intensity of fluorescence was reduced upon competition by bovine serum albumin (BSA).
Fig. 5. Fluorescein isothiocyanate (FITC)-D-Phe1-octreotide lysosomal localization by confocal microscopy. Living cells were pre-incubated for
60 minutes with LysoTracker red. (A) Lysosomes detected by LysoTracker red. (B) Detection of FITC-D-Phe1-octreotide. (C) Merge; yellow
fluorescence indicates localization of octreotide in lysosomes (arrowheads).
analogues undergo extensive glomerular ultrafiltration
but most is excreted intact in urine and only a small
percentage (∼2%) is retained in the kidneys, suggesting
that the mechanism of tubular reuptake is rather ineffi-
cient. Nevertheless, with the high dosages used for ther-
apy, even this small fraction retained leads to intensive
local irradiation including the radiosensitive glomeruli
by the radioactivity trapped in tubules, thereby caus-
ing chronic nephrotoxicity [4, 5]. The present study at-
tempted to better understand the mechanisms of renal
reabsorption of radiolabeled somatostatin analogues in
a well-differentiated PTC-derived cell line that expresses
megalin/cubilin, by focusing on (1) the kinetics of endocy-
tosis and the fate of internalized tracers; (2) the effect of
several maneuvers to reduce this uptake; (3) the compar-
ison with ligands known to be reabsorbed by receptor-
mediated endocytosis via the megalin/cubilin tandem;
and (4) the localization of a fluorescent octreotide ana-
logue by confocal microscopy.
The first issue of this work was to determine the ki-
netics of internalization and the fate of radiolabeled
somatostatin analogues in OK cells. We showed that
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111In-DTPA-D-Phe1-octreotide is internalized by endo-
cytosis as shown by its temperature dependence, and
accumulates with kinetics comparable to that of 125I-
HSA reaching a plateau after 2 hours. For 125I-HSA,
this plateau clearly reflects a balance between entry
and degradation [30]. In contrast, 111In-DTPA-D-Phe1-
octreotide is only partially released and cell-associated
tracer remains largely intact. After injection to mice, D
somatostatin analogues have been reported to accumu-
late in lysosomal fractions [11] and to remarkably resist
degradation. Our confocal microscopy study confirms the
transfer to lysosomes in the OK cells, as shown by colo-
calization with the lysosomal vital stain, LysoTracker
red. That the marginal degradation takes place in these
structures is supported by its sensitivity to chloroquine.
A second issue was to evaluate whether endocytosis of
radiolabeled somatostatin analogues in OK cells is medi-
ated by a specific somatostatin receptor or by the mul-
tifunctional megalin/cubilin receptor. High-affinity so-
matostatin binding sites have been reported in the OK
cell line [31]. However, our competition studies showed
that up to 100,000-fold molar excess cold octreotide only
marginally inhibited the uptake of 111In-DTPA-D-Phe1-
octreotide. We also observed modest competition by so-
matostatin itself (SMS 14) that exhibits a high-affinity (in
the nanomolar or low micromolar range) for all SSTRs.
Since octreotide shows the highest affinity for the SSTR2
(in the nanomolar range) [32], a significant role of SSTR2
on OK cells is unlikely. In agreement with this predic-
tion, we failed to detect SSTR2 by RT-PCR. Moreover,
the level of uptake of 111In-DTPA-D-Phe1-octreotide by
OK cells was quite low (∼0.1% of the tracer), that is far
below the level observed by in vitro experiments using
somatostatin receptor-expressing tumor cells (e.g., ∼7%
activity/mg protein in the case of the CA20948 cell line)
[33].
In contrast, our data strongly suggest a role of the me-
galin/cubilin complex in the renal uptake of somatostatin
analogues. Megalin is a key scavenger receptor for tubu-
lar reabsorption of such diverse molecules as albumin,
insulin, retinol- and vitamin D-binding proteins, or poly-
basic drugs such as polymixin B [29, 34–36]. A common
feature for all these megalin ligands is the presence of
basic patches that allow for the primary interaction with
negatively charged sites on megalin. Octreotide is also a
basic peptide, with an isoelectric point at 8.29. All megalin
and/or cubilin ligands tested including RAP, albumin,
transferrin, insulin, polymixin B essentially abrogated
125I-HSA uptake at a 100-fold molar excess but only de-
creased 111In-DTPA-D-Phe1-octreotide uptake by ∼50%
even at a 100,000-fold molar excess. Noticeably, RAP
suppressed 125I-HSA uptake at equimolar concentration
but was only a partial competitor of 111In-DTPA-D-Phe1-
octreotide uptake at a huge molar excess. A partial role
of the megalin/cubilin complex in the internalization of
octreotide by OK cells is consistent with our confocal mi-
croscopic study that showed a partial colocalization of
a fluorescent octreotide derivative with transferrin in the
early endosomal compartment and inhibition of their up-
take by albumin.
Amino acid solutions containing large amounts of basic
amino acids have been used in clinical trials for renal pro-
tection when using high activities of labeled somatostatin
analogues [10]. Our in vitro experiments confirm the po-
tential of amino acids solution containing 10 mmol/L L-
arginine to significantly decrease (by ∼30%) the uptake
of 111In-DTPA-D-Phe1-octreotide, while that of 125I-HSA
was efficiently inhibited (by ∼70%). This effect is likely
to occur by multiple noncovalent interactions of the basic
amino acids with the negative charges on the extracellular
domain of megalin.
Since only ∼ half of 111In-DTPA-D-Phe1-octreotide up-
take by OK cells was sensitive to competition by various
megalin/cubilin ligands that were effective to prevent up-
take of 125I-HSA, and since octreotide was a poor com-
petitor of itself, residual level that was refractory to all
maneuvers competing with potential receptors is likely
to reflect fluid-phase endocytosis. This conclusion is fully
confirmed by a level of clearance similar to that of the
fluid-phase tracer, Lucifer Yellow, as reported previously
[28].
CONCLUSION
These results suggest that two endocytic mechanisms
concomitantly contribute to the reabsorption of radiola-
beled somatostatin analogues by PTC: receptor-mediated
endocytosis via megalin/cubilin interaction and fluid-
phase endocytosis. In the case of OK cells, the two
mechanisms are of comparable importance. Although the
contribution of fluid-phase endocytosis could be much
lower in the kidney as shown in mouse studies for FITC-
dextran [14], due to a much higher rate of endocytosis in
kidney as compared to the cell line, it may still, in quanti-
tative terms, significantly contribute to the radiolabeled
somatostatin analogues uptake. Clearly, only receptor-
mediated endocytosis by the megalin/cubilin system can
be exploited to inhibit uptake of these analogues in order
to prevent renal toxicity associated with tumor-targeted
radiotherapy by somatostatin analogues. It is indeed not
possible with current means to prevent uptake by fluid-
phase endocytosis, which is an endocytic constant that
does not depend on interaction of the tracer with the
cellular membrane. Although in vitro data on an immor-
talized heterologous cell line cannot be directly extrapo-
lated without much caution to in vivo processing system
by the human kidney, our results are consistent with the
observation that attempts to prevent renal reuptake of a
labeled somatostatin analogue did not exceeded ∼50%
decrease [10]. Further research is required to maximize
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the effects of maneuvers aiming at preventing kidney up-
take of currently available somatostatin analogues, or to
define alternative compounds with lower affinity for the
megalin/cubilin system.
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